Canada's largest open-access rural networks upgraded with advanced routing and switching layers to enhance performance and resilience
SANTA CLARA, Calif., December 10, 2024 – IP Infusion, a global leader in open networking solutions, announced today that solution integrator and managed service operator Dataduct Networks is modernizing Nova Scotia's fiber network with IP Infusion's advanced networking software. This system upgrade, architected in collaboration with open networking provider FONEX, enables integration of hardware from multiple vendors and implementation of sophisticated features for scalability and resiliency.
The upgrade introduces advanced networking capabilities, including Ethernet VPN (EVPN) and Segment Routing MPLS (SR-MPLS). These technologies automate redundancy, ensuring rapid failover during network disruptions and significantly reducing downtime. IP Infusion's software powered the deployment of SR-MPLS, enhancing overall network resilience while reducing operational burdens on Dataduct Networks' engineering teams.
Beyond SR-MPLS, IP Infusion's rich feature set enables Dataduct Networks to optimize and manage the network effectively. Customizable tools support traffic engineering, network slicing, and enhanced security protocols, allowing operators to tailor the system to their specific needs.
"This project demonstrates the importance of selecting the right software to tackle complex networking challenges and secure long-term operational success," said Richard Bourret, CEO of Dataduct Networks. "As a market leader, we found IP Infusion, with FONEX's support, to be the ideal long-term partner for this deployment."
"With IP Infusion and FONEX, Dataduct Networks successfully modernized the county's optical broadband network. The flexibility of open networking solutions proved invaluable for system upgrades like this," said Pasquale Di Pierro, CEO of FONEX. "IP Infusion's domain expertise in open networking operating systems and its performance have proven to be highly competitive in today's networking market."
"Intelligent networking software from IP Infusion transforms the value proposition for network upgrades," said Atsushi Ogata, President and CEO of IP Infusion. "Built on open computing standards, OcNOS guarantees both immediate value and long-term stability."
IP Infusion 소개
IP Infusion develops open network software solutions for carriers, service providers, and data centers. With hundreds of customers and thousands of deployments, IP Infusion leads the market in Network Operating Systems. Its flagship platform, OcNOS®, empowers network operators to disaggregate their networks, streamline operations, and reduce total cost of ownership (TCO). Headquartered in Santa Clara, Calif., IP Infusion is a wholly owned subsidiary of ACCESS CO., LTD. For more information, visit www.ipinfusion.com/.
About Dataduct Networks
Dataduct Networks is a leading solution integrator and managed service operator specializing in the design, deployment, and management of cutting-edge communication infrastructure. Committed to bridging the digital divide, Dataduct Networks delivers high-speed internet access to underserved communities and provides mission-critical services for municipalities and utilities. www.dataduct.io
About FONEX
FONEX Data Systems delivers innovative network infrastructure design solutions for service providers. Its carrier-grade portfolio, combined with in-house technical expertise, positions FONEX as a trusted partner for telecom solutions across Canada and Europe. For more information, visit www.fonex.com.
미디어 문의
Katherine Verducci
1903 PR
kverducci@1903pr.com
408.429.5779
IP Infusion 소개
IP Infusion은 오픈 네트워킹 소프트웨어의 선도적 공급업체로서, 서비스 프로바이더, 데이터센터, AI 패브릭 네트워크를 위한 캐리어급 네트워크 운영체제인 OcNOS를 제공합니다. 26+ 년의 네트워킹 전문성과 전 세계 600+ 오퍼레이터 실적을 바탕으로, Edgecore Networks, UfiSpace, Celestica 등 파트너의 검증된 오픈 하드웨어에서 개방적이고 멀티벤더이며 비용 효율적이고 유연한 네트워크 인프라를 구현합니다. IP Infusion은 ACCESS CO., LTD.(도쿄증권거래소: 4813)의 완전 자회사입니다.
미디어 문의
For press inquiries, analyst briefings, or media materials, please 팀에 문의 or email pr@ipinfusion.com.
미래예측 진술
본 보도자료에는 IP Infusion의 제품, 기술 및 계획에 관한 미래예측 진술이 포함될 수 있습니다. 미래예측 진술은 공개일 현재 이용 가능한 정보에 기초하며 위험과 불확실성을 수반합니다. 실제 결과는 다를 수 있습니다. 제품 계획, 기능, 출시 시기 및 제공 여부는 예고 없이 변경될 수 있으며 약정, 약속 또는 법적 의무를 구성하지 않습니다. IP Infusion은 미래예측 진술을 갱신할 의무를 지지 않습니다.